Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 803-811

  Bramlage, Peter ^a   Wolf, Wolf Peter ^b   Stuhr, Thomas ^b   Fronk, Eva Maria ^b   Erdlenbruch, Wolfhard ^b   Ketelhut, Reinhard ^c   Schmieder, Roland E ^d  

^a Institute for Cardiovascular Pharmacology and Epidemiology   (Germany)

^b DAIICHI SANKYO CO   (Japan)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Antihypertensive treatment; Blood pressure; Cardiovascular risk; Observation

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS OLMESARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; OLMESARTAN; PLACEBO; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; BREAST DISEASE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COMORBIDITY; CONNECTIVE TISSUE DISEASE; CORRELATION ANALYSIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR DISEASE; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; HYPERTENSION; IMMUNOPATHOLOGY; INFECTION; INNER EAR DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OBSERVATIONAL STUDY; PERIPHERAL EDEMA; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; RESPIRATORY TRACT DISEASE; RISK FACTOR; SKIN DISEASE; THORAX DISEASE; TREATMENT DURATION; VASCULAR DISEASE; AGED; BLOOD PRESSURE; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; MIDDLE AGED; TREATMENT OUTCOME;

AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; TETRAZOLES; TREATMENT OUTCOME;

EID: 78149421109     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S13441     Document Type: Article

References (17)

1. Mancia G, de Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
2. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. Blood Press. 2009;18:308-347.
3. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-2428.
4. Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebocontrolled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30:587-604.
5. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521-530.
6. Mathes J, Kostev K, Gabriel A, Pirk O, Schmieder RE. Relation of the first hypertension-associated event with medication, compliance and persistence in naive hypertensive patients after initiating monotherapy. Int J Clin Pharmacol Ther. 2010;48:173-183.
7. Barrios V, Brommer P, Haag U, Calderon A, Escobar C. Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderateto- severe hypertension after monotherapy: A randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig. 2009;29:427-439.
8. Chrysant SG, Oparil S, Melino M, Karki S, Lee J, Heyrman R. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens (Greenwich). 2009;11:475-482.
9. Mourad JJ, Le Jeune S. Effective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: Post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig. 2009;29:419-425.
10. Oparil S, Lee J, Karki S, Melino M. Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: Evaluation by baseline hypertension stageand prior antihypertensive medication use. J Cardiovasc Pharmacol. 2009;54:427-436.
11. Volpe M, Brommer P, Haag U, Miele C. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: A randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig. 2009;29:11-25.
12. Chrysant SG, Lee J, Melino M, Karki S, Heyrman R. Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. J Hum Hypertens. 2010 Feb 18. [Epub ahead of print].
13. Puchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens Suppl. 2001;19:S41-S48.
14. Schindler C, Ferrario CM. Olmesartan for the treatment of arterial hypertension. Future Cardiol. 2008;4:357-372.
15. Pedrinelli R, Dell'Omo G, Mariani M. Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension. J Hum Hypertens. 2001;15:455-461.
16. Messerli FH. Vasodilatory edema: A common side effect of antihypertensive therapy. Am J Hypertens. 2001;14:978-979.
17. Weir MR. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: Issues and practical significance. J Clin Hypertens (Greenwich). 2003;5:330-335.